Once-weekly dual GIP and GLP-1 receptor agonist that improves glycemic control and drives weight loss.

Long-acting GLP-1 receptor agonist with amino-acid substitutions and fatty-acid side chain for albumin binding.

Once-weekly triple agonist of GLP-1, GIP, and glucagon receptors in development for obesity and related conditions.

Fixed-dose combination of long-acting amylin analogue cagrilintide and semaglutide for enhanced weight loss.

OXM-derived dual GLP-1 and glucagon receptor agonist licensed from Eli Lilly and developed in China.

Oral small-molecule GLP-1 receptor agonist being evaluated in twice-daily and once-daily formulations.

Once-daily oral small-molecule GLP-1 receptor agonist discontinued after phase 2 due to liver enzyme elevations.

Novel dual GLP-1/glucagon receptor agonist peptide co-developed for obesity and NASH/MASH.

Anti-GIPR monoclonal antibody conjugated to two GLP-1 agonist peptides, designed for monthly dosing.

Once-weekly injectable dual GIP/GLP-1 receptor agonist acquired by Roche with Carmot Therapeutics.

Orally bioavailable small-molecule GLP-1 receptor agonist discovered using structure-based design.

Oral small-molecule GLP-1 receptor agonist advanced by Eli Lilly into phase 3 for obesity and type 2 diabetes.

Novel dual GLP-1 and glucagon receptor agonist peptide with a pulmonary-shunt stabilizing albumin binder.

Pegylated dual GLP-1/glucagon receptor agonist peptide evaluated in NASH/MASH and metabolic disease.

SNAC-enabled oral formulation of semaglutide providing GLP-1 receptor agonism via the gut.